Sankyo Japan

Has Ranbaxy been taken over by Japan’s Daiichi Sankyo?

daiichi, daiichi sankyo, ranbaxy news, ranbaxy daiichi, daichi,daiichi, daiichi sankyo, ranbaxy news, ranbaxy daiichi, daichi,ranbaxy sold

yes.
check out
http://zdark.blogspot.com/2008/06/indian-drugs-maker-ranbaxy-taken-over.html

Pharmaceutical Power of Japan Daiichi Sankyo's acquisition of Ranbaxy Laboratories, the largest pharmaceutical company in India is likely to have a domino effect on mergers and acquisitions of Indian pharmaceutical companies. The business model that led to the kitty of Ranbaxy mega influence U.S. dollars in other industry companies to follow suit.

Ranbaxy is one of the few companies in India that have a global presence in generic drugs. However, his decision to resign from the controlling stake to another multinational company, shows that do business in India with the rules is difficult and less lucrative. While India produced about eight drugs in overall costs, the Indian government insisted that the policies to control prices. Some Industry experts said the price controls to some extent, Indian pharmaceutical business has made less attractive.

By contrast, hasita Joshipura, Managing Director of GlaxoSmithKline said, the agreement of Mylan, Matrix and Ranbaxy deal now confirm that global pharmaceutical companies in India seeking from another angle, in itself, recognition of the country as a key destination for pharmacy. The global pharmaceutical players would be very interested in investing in India, either through the creation of its wholly owned entities, or strategic alliance agreements or acquisitions.

India has become more attractive in the eyes of drug companies in the world due to the ability of India to manufacture drugs at very low cost and availability of quality English speaking staff scientist with the required skills. Whereas, over pharmacy have to live with rising manufacturing costs in the country that has forced aa search viable elsewhere, such as India to maintain momentum in their businesses.

Vice President and General Manager of Novartis India Ranjit Shahani said Indian generic players with established global firms have undoubtedly been a target for multinational enterprises to enhance their business. The coming months will transform the industry Indian pharmaceutical business with more than those predicted Shahani.

When India introduced product patent regime in 2005, the Indian pharmaceutical companies had to swallow the bitter pill that prevent them from carrying out generic versions of patented drugs. The drug discovery process, and the drug development process involving billions of dollars and prevented Indian companies to exercise such processes in a highly competitive market global generic. There are many big names in the Indian pharmaceutical industry including Aurobindo Pharma, Cipla and Orchid Chemicals & Pharmaceuticals have been the subject of business multinational for a while. Higher scores have been deferred by these companies to be acquired so far.

Malvinder Mohan Singh, CEO and MD of Ranbaxy is believed business model that it shares with Daiichi Sankyo would be replicated by many other companies, large and small industry. CEO & MD of Glen Saldanha of Glenmark deal that especially small players would be forced out of business, and only the fundamentally strong companies might be able to stay in the generic market in the future.

Though many industrialists felt anguish over the sale of Ranbaxy, however, added, earning good profits in the process should be considered that other aspects in a highly competitive pharmacy business. Many big global drug without generic drugs in its portfolio and various problems encountered by Indian pharmaceutical companies combined will create a perfect backdrop to redefine the 50 billion U.S. dollars Indian pharmaceutical business in the near future.

About the Author:

Want to setup a Company or Office in other country? Visit the Business Services database of the B2B Trade Portal. We can help you in this.

Article Source: ArticlesBase.com – Ranbaxy Aftershocks- Indian Drug Makers is Up for Grabs